NCT04309669已完成4 期
Assessment of the eFficacy, the Onset-of-Action and the Safety of Tot'héma® in Adults With Moderate Iron Deficiency Anaemia
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 167
- 试验地点
- 1
- 主要终点
- Time required for a mean increase of at least 0,5g/dL from baseline in the haemoglobin level in patients with moderate IDA and daily treated with Tot'héma.
研究概览
简要总结
The aim of this study is to assess, in patients with moderate IDA, the Onset-of-Action of a daily treatment with Tot'Héma®. The onset of action is defined as the time required for a mean increase of at least 0,5g/dL from baseline in the haemoglobin level.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult men and women (>18 years)
- •Patient with a confirmation of moderate anemia defined as: 8 g/dL ≤ Haemoglobin level ≤ 9 g/dL on the last hematological test performed within 7 days before inclusion visit.
- •Patient with ferritin blood level < lower limit of laboratory standard for this biological parameter at on the last hematological test performed within 7 days before inclusion visit.
- •Patient who has read, understood, dated and signed the informed consent form
- •Patient agreeing to comply with protocol requirements, including visits and blood samples at specifically defined dates
- •Non-inclusion Criteria:
- •Patient for whose an oral iron supplementation is not indicated or not recommended according to PI's opinion
- •CRP > 10 mg/L on the last hematological test performed within 7 days before inclusion visit.
- •Patient with benign or malignant neoplastic tumour
- •Patient presenting gastrointestinal disorders incompatible with study treatment compliance
- •Pregnant or breastfeeding woman
- •Woman with childbearing potential who does not agree to use an accepted highly effective method of contraception - per investigator's judgment
- •Patient with surgery scheduled to occur during the treatment period
- •Patient allergic or hypersensitive to any of the components of Tot'Héma® ampoule
- •Patient with chronic inflammatory disease, including chronic inflammatory bowel syndrome and/or chronic heart failure and/or chronic renal failure and/or inflammatory rheumatism
- •Patient with active digestive bleeding (such as digestive ulcer)
- •Patient having taken iron supplementation, iron-based IV therapy or mineral supplementation with iron, within the 15 days prior to the inclusion visit (V2)
- •Patient with fructose intolerance, glucose-galactose malabsorption syndrome or sucrase-isomaltase deficiency
- •Patient with acute malaria crisis within 15 days prior to inclusion
- •Patient with a positive Faecal Occult Blood Test (FOBT)
- •Patient with HIV infection
- •Unreliable patients, including non-observant patients, patients with known alcoholism or drug abuse, or with a history of a serious psychiatric disorder, as well as patients who are reluctant to give informed consent or to comply with protocol requirement.
- •Selection criterion
- •Patient with moderate anaemia defined as 8 g/dL ≤ haemoglobin level ≤ 9 g/dL on the last hematological test performed within 7 days before screening visit
- •Inclusion criteria
- •Adult men and women (≥18 years)
- •Patient with a confirmation of moderate anaemia defined as 8 g/dL ≤ haemoglobin level ≤ 9 g/dL on the last hematological test performed within 7 days before inclusion visit
- •Patient with ferritin blood level < lower limit of laboratory standard for this biological parameter on the last hematological test performed within 7 days before inclusion visit
- •Patient who has read, understood, dated and signed the informed consent form
- •Patient agreeing to comply with protocol requirements, including visits and blood samples at specifically defined dates Non-inclusion criteria
- •Patient for whom an oral iron supplementation is not indicated or not recommended according to Investigator's opinion
- •C-Reactive Protein > 10 mg/L on the last hematological test performed within 7 days before inclusion visit
- •Patient with benign or malignant neoplastic tumour
- •Patient presenting gastrointestinal disorders incompatible with study treatment compliance
- •Pregnant or breastfeeding woman
- •Woman with childbearing potential who does not agree to use an accepted highly effective method of contraception - per investigator's judgment
- •Patient with surgery scheduled to occur during the treatment period
- •Patient allergic or hypersensitive to any of the components of Tot'héma® ampoule
- •Patient with chronic inflammatory disease, including chronic inflammatory bowel syndrome and/or chronic heart failure and/or chronic renal failure and/or inflammatory rheumatism
- •Patient with active digestive bleeding (such as digestive ulcer)
- •Patient having taken iron supplementation, iron-based IV therapy mineral supplementation with iron within the 15 days prior to the inclusion visit (V2)
- •Patient with fructose intolerance, glucose-galactose malabsorption syndrome or sucrase-isomaltase deficiency
- •Patient with acute malaria crisis within 15 days prior to inclusion
- •Patient with a positive Faecal Occult Blood Test (FOBT)
- •Patient with HIV infection
- •Unreliable patients, including non-observant patients, patients with known alcoholism or drug abuse, or with a history of a serious psychiatric disorder, as well as patients who are reluctant to give informed consent or to comply with protocol requirement.
- •Patient with a family relationship to a person at the investigator's site or at the Sponsor or at the CRO.
- •Participant involved in another interventional or observational clinical trial or who participated in another interventional clinical trial within four weeks before inclusion.
排除标准
- 未提供
研究组 & 干预措施
Tot'hema
Experimental
three ampoules per day during 12 weeks daily dose: 150mg of iron per day.
干预措施: TOT'HEMA (Drug)
结局指标
主要结局
Time required for a mean increase of at least 0,5g/dL from baseline in the haemoglobin level in patients with moderate IDA and daily treated with Tot'héma.
时间窗: 12 weeks
Identification of the first time (in days) associated with a mean increase in the haemoglobin level of at least 0.5 g/dL (versus mean haemoglobin level at D0).
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch TestKidney Failure, ChronicNCT02790437Hansa Biopharma AB19
已完成
1 期
Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic LeukemiaNCT00046488Biogen70
进行中（未招募）
1 期
Assessment of the eFficacy, the onset-of-Action and the Safety of Tot'héma ® in adults with moderate iron deficiency anaemiaModerate iron deficiency anaemiaMedDRA version: 20.0Level: LLTClassification code 10002062Term: Anaemia iron deficiencySystem Organ Class: 100000004851EUCTR2019-003202-27-FRaboratoire Innotech Internationnal270
进行中（未招募）
1 期
Assessment of the eFficacy, the onset-of-Action and the Safety of Tot'héma ® in adults with moderate iron deficiency anaemiaModerate iron deficiency anaemiaMedDRA version: 20.0Level: LLTClassification code 10002062Term: Anaemia iron deficiencySystem Organ Class: 100000004851EUCTR2019-003202-27-BGaboratoire Innotech Internationnal121
进行中（未招募）
1 期
LEARNER- Low dosE AspiRiN prEterm tRial (Angola)Pregnancy RelatedPregnancy ComplicationsSickle Cell DiseasePre-EclampsiaNCT06417411Instituto Nacional de Investigacao em Saude, Angola450